3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
297
Lung Neoplasms
195
Colorectal Neoplasms
54
Small Cell Lung Carcinoma
52
Neoplasms
39
Ovarian Neoplasms
38
Melanoma
37
Pancreatic Neoplasms
33
Breast Neoplasms
31
Neoplasm Metastasis
27
Stomach Neoplasms
26
Squamous Cell Carcinoma of Head and Neck
24
Carcinoma, Renal Cell
22
Urinary Bladder Neoplasms
20
Prostatic Neoplasms
20
Esophageal Neoplasms
20
Endometrial Neoplasms
20
Head and Neck Neoplasms
19
Triple Negative Breast Neoplasms
18
Colonic Neoplasms
18
Uterine Cervical Neoplasms
16
Carcinoma, Hepatocellular
16
Mesothelioma
15
Lung Diseases
13
Sarcoma
12
Parkinson Disease 4, Autosomal Dominant Lewy Body
12
Mesothelioma, Malignant
12
Adenocarcinoma of Lung
11
Cholangiocarcinoma
10
Rectal Neoplasms
9
Interventions
durvalumab
1
cemiplimab
1
atezolizumab
1
Pemetrexed
1
Nivolumab
1
Docetaxel
1
Cisplatin
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Vaccinia
×
Thoracic
×
30 days
×
Clear all
NCT06463665
2026-06-04
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled